BS_QSTAVWGE
Spinal Cord Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Spinal Cord Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Spinal Cord Ependymoma
- overall_survival_months
- 140.76872536136662
- age_years
- 8.611
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.414
- WNT_BETA_CATENIN_SIGNALING+0.365
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.296
- ANGIOGENESIS+0.265
- HYPOXIA+0.254
- P53_PATHWAY+0.254
- NOTCH_SIGNALING+0.229
- DNA_REPAIR+0.224
- GLYCOLYSIS+0.211
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.197
Top 10 suppressed
- G2M_CHECKPOINT-0.361
- MITOTIC_SPINDLE-0.321
- E2F_TARGETS-0.290
- KRAS_SIGNALING_UP-0.245
- ALLOGRAFT_REJECTION-0.232
- ANDROGEN_RESPONSE-0.216
- INFLAMMATORY_RESPONSE-0.183
- COMPLEMENT-0.168
- MTORC1_SIGNALING-0.151
- MYC_TARGETS_V1-0.151
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QSTAVWGE | EPN | EPN Tumor | 0.873 |
| 2 | BS_MA2T7ET1 | Spinal Cord Ependymoma | — | 0.771 |
| 3 | BS_8ZP3CBQA | Posterior Fossa Ependymoma | — | 0.711 |
| 4 | f0f41799-29e8-43f9-b357-722df163e963 | — | — | 0.694 |
| 5 | SRR8943013 | — | — | 0.668 |
| 6 | 9c8140ab-454c-4f62-aa6e-d1cfe4e498e0 | — | — | 0.666 |
| 7 | 1e82995c-f318-4225-96d4-f1e98bcbf60b | — | — | 0.665 |
| 8 | ERR2598127 | fetal | fetal | 0.664 |
| 9 | BS_P78SMRBS | Spinal Cord Ependymoma | — | 0.654 |
| 10 | 8f45c6c4-b98d-4e0b-9bb0-b5be3894076d | — | — | 0.651 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.414 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.365 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.296 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.265 | Remibrutinib | — uncovered |
| HYPOXIA | 0.254 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.254 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.229 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.224 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.211 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.197 | Inavolisib | — uncovered |
| COAGULATION | 0.194 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.167 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.158 | Inavolisib | — uncovered |
| MYOGENESIS | 0.137 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.115 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.111 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.097 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.095 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.095 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.094 | Inavolisib | — uncovered |